In the last trading session, 3.35 million shares of the Blueprint Medicines Corp (NASDAQ:BPMC) were traded, and its beta was 0.85. Most recently the company’s share price was $128.23, and it changed around -$0.02 or -0.02% from the last close, which brings the market valuation of the company to $8.29B. BPMC currently trades at a discount to its 52-week high of $128.34, offering almost -0.09% off that amount. The share price’s 52-week low was $73.04, which indicates that the current value has risen by an impressive 43.04% since then. We note from Blueprint Medicines Corp’s average daily trading volume that its 10-day average is 4.98 million shares, with the 3-month average coming to 2.57 million.
Blueprint Medicines Corp stock received a consensus recommendation rating of Hold, based on a mean score of 2.84. If we narrow it down even further, the data shows that 1 out of 31 analysts rate the stock as a Sell; another 6 rate it as Overweight. Among the rest, 15 recommended BPMC as a Hold, whereas 9 deemed it a Buy, and 0 rated it as Underweight.
Blueprint Medicines Corp (NASDAQ:BPMC) trade information
Instantly BPMC has showed a red trend with a performance of -0.02% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 128.34 on recent trading dayincreased the stock’s daily price by 0.09%. The company’s shares are currently up 47.02% year-to-date, but still up 0.20% over the last five days. On the other hand, Blueprint Medicines Corp (NASDAQ:BPMC) is 26.10% up in the 30-day period. We can see from the shorts that 6.08 million shares have been sold at a short interest cover period of 7.19 day(s).
The consensus price target as assigned by Wall Street analysts is $141, which translates to bulls needing to increase their stock price by 9.06% from its current value. Analyst projections state that BPMC is forecast to be at a low of $132 and a high of $150.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 31.87%.
BPMC Dividends
Blueprint Medicines Corp’s next quarterly earnings report is expected to be released on 2025-Apr-30.
Blueprint Medicines Corp (NASDAQ:BPMC)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.86% of Blueprint Medicines Corp shares, and 109.40% of them are in the hands of institutional investors. The stock currently has a share float of 110.36%. Blueprint Medicines Corp stock is held by 490.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 10.5758% of the shares, which is about 6.65 million shares worth $716.45 million.
VANGUARD GROUP INC, with 10.4026% or 6.54 million shares worth $704.72 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
